Skip to content
  • Investors
  • Careers
  • Contact Us
  • TW
  • LI
  • WC
Apollomics Pharmaceuticals
  • Our Company
    • About Us
    • Management
    • Board of Directors
    • Scientific and Clinical Advisors
    • Our Partners
    • Apollomics China
    • Contact
  • Our Science
    • Our Approach
    • Publications
  • Our Pipeline
    • R&D Pipeline
    • APL-101 (c-METi)
    • APL-102 (mKi)
    • APL-106 (uproleselan)
    • APL-501 (PD-1)
  • Investors
  • News/Events
    • Press Releases
    • Events & Presentations
    • Community
  • Contact
  • English
    • 简体中文
×
  • Our Company
    • About Us
    • Management
    • Board of Directors
    • Scientific and Clinical Advisors
    • Our Partners
    • Apollomics China
    • Contact
  • Our Science
    • Our Approach
    • Publications
  • Our Pipeline
    • R&D Pipeline
    • APL-101 (c-METi)
    • APL-102 (mKi)
    • APL-106 (uproleselan)
    • APL-501 (PD-1)
  • Investors
  • News/Events
    • Press Releases
    • Events & Presentations
    • Community
  • Contact
  • English
    • 简体中文

Publications

APL-101 (c-METi)

ENA 2020:
Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor
Cell:
November 2018
Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor
SITC 2018:
Combination immunotherapy anti-PD-1 antibody with CBT-101 (c-MET inhibitor) demonstrates enhanced activity in tumors not dependent on c-MET
AACR 2017:
Bozitinib, a highly selective inhibitor of c-MET, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models

APL-102 (mKi)

AACR 2019:
APL-102, an oral small molecule multi-kinase inhibitor, demonstrates favorable CSF-1R activity, offering a means for controlling tumor associated macrophages
AACR 2018:
CBT-102, an oral multi-kinase small molecule, demonstrates favorable activity in LIMsh050 and PLCPRF5 human hepatocellular carcinoma animal models and cardiac safety in rabbit Purkinje and Beagle dogs compared to sorafenib

APL-501 (PD-1)

SITC 2017:
A phase 1 multicenter, dose escalation study of CBT-501, a novel anti-PD-1 inhibitor in subjects with select advanced or relapsed/recurrent solid tumors
ASCO-SITC 2017:
CBT-501, a novel humanized anti-PD-1 antibody shows differentiated activity in a humanized genetically engineered mouse model of colon carcinoma

* For questions related to our publications, please contact our Medical Affairs team at [email protected].

Apollomics Pharmaceuticals

our company
management
board of directors
scientific & clinical advisors
our partners
apollomics china

our approach
publications

our pipeline
APOLLO
APL-101 (c-METi)
APL-102 (MTKi)
APL-106 (uproleselan)
APL-501 (PD-1)

news & events
press releases
events
presentations

join our team
opportunities

contact us
Apollomics, Inc.
989 East Hillsdale Blvd. Ste 220
Foster City, CA 94404 USA
+1.650.209.4055 phone
+1.650.288.1674 fax

© 2023 Apollomics, Inc.  All Rights Reserved. • Privacy Policy

Apollomics Careers
  • To apply for any of our open positions, please complete the form below and click the Join Apollomics button at the bottom.

    Your information will be reviewed within 1-3 business days.

    Thank you for your interest in joining the team at Apollomics, Inc. team.

  • Max. file size: 1 GB.
    Upload your resume or curriculum vitae here.
  • This field is for validation purposes and should be left unchanged.